Clinical significance of antimicrobial resistance in Streptococcus pneumoniae

South African Medical Journal

Volumn 97, Issue 11 III, 2007, Pages 1133-1140

  Jacobs, Michael R ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFIXIME; CEFPROZIL; CEFTRIAXONE; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ETHYLHYDROCUPREINE; LINCOSAMIDE; LINEZOLID; MACROLIDE; PENICILLIN G; PENICILLIN V; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULFONAMIDE; TELITHROMYCIN; TETRACYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ACUTE OTITIS MEDIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL MENINGITIS; BACTERIAL VIRULENCE; CHRONIC BRONCHITIS; COMMUNITY ACQUIRED PNEUMONIA; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EMPIRICISM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; PATIENT COMPLIANCE; PHARMACODYNAMICS; PRACTICE GUIDELINE; SEROTYPE; SINUSITIS; STRAIN DIFFERENCE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MENINGITIS, PNEUMOCOCCAL; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, BACTERIAL; SINUSITIS; STREPTOCOCCUS PNEUMONIAE;

EID: 37349077549     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Dagan R, Greenberg D, Jacobs MR. Streptococcus pneumoniae. In: Feigin RD, Cherry JD, Demmler GJ, Kaplan SL, eds. Textbook of Pediatric Infectious Disease. 3rd ed.. Philadelphia: WB Saunders, 2004: 1204-1258.
2. Jacobs MR. Drug-resistant Streptococcus pneumoniae: rational antibiotic choices. Am J Med 1999; 106(5A): 19S-25S; discussion 48S-52S.
3. Rudan I, Tomaskovic L, Boschi-Pinto C, Campbell H. Global estimate of the incidence of clinical pneumonia among children under five years of age. Bull World Health Organ 2004; 82(12): 895-903.
4. Centers for Disease Control. Active Bacterial Core Surveillance (ABCS) Report Emerging Infections Program Network Streptococcus pneumoniae, 2005 http://www.cdc.gov/ncidod/dbmd/abcs/survreports/ spneu05.pdf. 2006. Accessed 6 July 2007.
5. Ekdahl K, Ahlinder I, Hansson HB, et al. Duration of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae: experiences from the South Swedish Pneumococcal Intervention Project. Clin Infect Dis 1997; 25(5):1113-1117.
6. Hausdorff WP, Yothers G, Dagan K, et al. Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr Infect Dis J 2002; 21(11): 1008-1016.
7. Fleming A. Vaccine Therapy. In: Fleming A, Petrie GF. eds. Recent Advances in Vaccine and Serum Therapy. London: J & A Churchill, 1934: 298-308.
8. Austrian R. Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Rev Infect Dis 1981; 3 Suppl: S1-17.
9. Watson DA, Musher DM, Jacobson JW, Verhoef J. A brief history of the pneumococcus in biomedical research: a panoply of scientific discovery. Clin Infect Dis 1993; 17(5): 913-924.
10. Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA 2001; 285(13):1729-1735.
11. Shields B. Prevnar (heptavalent pneumococcal conjugate vaccine): disease prevention in infants and children. J Pediatr Health Care 2001; 15(4): 203-208; quiz 209-210.
12. Whitney CG. Impact of conjugate pneumococcal vaccines. Pediatr Infect Dis J 2005; 24(8): 729-730.
13. Pelton SI, Huot H, Finkelstein JA, et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007; 26(6): 468-472.
14. Messina AF, Katz-Gaynor K, Barton T, et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, Tex, children from 1999 through 2005. Pediatr Infect Dis J 2007; 26(6): 461-467.
15. Klugman KP. Clinical impact of antibiotic resistance in respiratory tract infections. Int J Antimicrob Agents 2007; 29 Suppl 1: S6-10.
16. Austrian R. The pneumococcus at the millennium: not down, not out. J Infect Dis 1999; 179 Suppl 2: S338-341.
17. Appelbaum PC, Bhamjee A, Scragg JN, Hallett AF, Bowen AJ, Cooper RC. Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet 1977; 2(8046): 995-997.
18. Jacobs MR, Koornhof HJ, Robins-Browne RM, et al. Emergence of multiply resistant pneumococci. N Engl J Med 1978; 299(14): 735-740.
19. American Academy of Pediatrics and American Academy of Family Physicians. Diagnosis and management of acute otitis media. Pediatrics 2004; 113(5):1451-1465.
20. Anon JB, Jacobs MR, Poole MD, et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004; 130(1 Suppl): 1-45.
21. Dagan K, Leibovitz E. Bacterial eradication in the treatment of otitis media. Lancet Infect Dis 2002; 2(10): 593-604.
22. Jacobs MR. Anti-infective pharmacodynamics - maximizing efficacy, minimizing toxicity. Drug Discovery Today 2004; 1(4): 505-512.
23. Jacobs MR, Anon J, Appelbaum PC. Mechanisms of resistance among respiratory tract pathogens. Clin Lab Med 2004; 24(2): 419-453.
24. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; 18th Informational Supplement. M100-S18. Wayne, Pa.: Clinical and Laboratory Standards Institute, 2008.
25. Johnson DM, Stilwell MG, Fritsche TR, Jones RN. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003). Diagn Microbiol Infect Dis 2006; 56(1): 69-74.
26. Song JH, Ko KS, Lee MY, et al. In vitro activities of ertapenem against drug-resistant Streptococcus pneumoniae and other respiratory pathogens from 12 Asian countries. Diagn Microbiol Infect Dis 2006; 56(4): 445-450.
27. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52(2): 229-246.
28. Schrag SJ, McGee L, Whitney CG, et al. Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin. Antimicrob Agents Chemother 2004; 48(8):3016-3023.
29. Jacobs MR. Increasing antibiotic resistance among otitis media pathogens and their susceptibility to oral agents based on pharmacodynamic parameters. Pediatr Infect Div J 2000; 19(5 Suppl): S47-55; discussion S55-56.
30. Schentag JJ, Klugman KP, Yu VL, et al. Streptococcus pneumoniae bacteraemia: pharmacodynamic correlations with outcome and macrolide resistance - a controlled study. Int J Antimicrob Agents 2007; 30(3): 264-269.
31. Daneman N, McGeer A, Green K, Low DE. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 2006; 43(4): 432-438.
32. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythtomycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35(5): 556-564.
33. Jacobs MR. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does resutt in clinical failure. Clin Infect Dis 2002; 35(5): 565-569.
34. Hoban DJ, Zhanel GG. Clinical implications of macrolide resistance in community-acquired respiratory tract infections. Expert Rev Anti Infect Ther 2006; 4(6): 973-980.
35. Gleason PP, Walters C, Heaton AH, Schafer JA. Telithromycin: the perils of hasty adoption and persistence of off-label prescribing. J Manag Care Pharm 2007; 13(5): 420-425.
36. Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis 2005; 41(1): 118-121.
37. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2: S27-72.
38. Lode HM. Managing community-acquired pneumonia: A European perspective. Respir Med 2007; 101: 1864-1873.
39. Bradley JS. Management of community-acquired pediatric pneumonia in an era of increasing antibiotic resistance and conjugate vaccines. Pediatr Infect Dis J 2002; 21(6): 592-598; discussion 613-614.
40. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39(9): 1267-1284.
41. Sethi S, Murphy TF. Acute exacerbations of chronic bronchitis: new developments concerning microbiology and pathophysiology - impact on approaches to risk stratification and therapy. Infect Dis Clin North Am 2004; 18(4): 861-882, ix.
42. Brunton S, Carmichael BP, Colgan R, et al. Acute exacerbation of chronic bronchitis: a primary care consensus guideline. Am J Manag Care 2004; 10(10): 689-696.
43. Peterson LR. Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter? Clin Infect Dis 2006; 42(2): 224-233.
44. Klugman KP, Yu VL. No impact of penicillin resistance on mortality. Clin Infect Dis 2006; 43(2): 261-262.
45. Chiou CC. Does penicillin remain the drug of choice for pneumococcal pneumonia in view of emerging in vitro resistance? Clin Infect Dis 2006; 42(2): 234-237.
46. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37(2): 230-237.
47. Reinert RR, Jacobs MR, Appelbaum PC, et al. Relationship between the original multiply resistant South African isolates of Streptococcus pneumoniae from 1977 to 1978 and contemporary international resistant clones. J Clin Microbiol 2005; 43(12): 6035-6041.
48. American Academy of Pediatrics. Section 3 Summaries of Infectious Diseases. Pneumococcal Infections. Red Book Online http://aapredbook.aappublications.org/cgi/content/full/2006/1/3.100#T3.47 2006. Accessed 6 July 2007.
49. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 2001; 7(11): 589-596.
50. Jones RN, Mutnick AH, Varnam DJ. Impact of modified nonmeningeal Streptococcus pneumoniae interpretive criteria (NCCLS M100-S12) on the susceptibility patterns of five parenteral cephalosporins: report from the SENTRY antimicrobial surveillance program (1997 to 2001). J Clin Microbiol 2002; 40(11): 4332-4333.
51. Pfaller MA, Jones RN. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide. Diagn Microbiol Infect Dis 1997; 28(4): 157-163.
52. Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect 2005; 11(12): 974-984.
53. Jones RN, Ross JE, Fritsche TR, Sader HS. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 2006; 57(2): 279-287.
54. Marchese A, Gualco L, Schito AM, Debbia EA, Schito GC. In vitro activity of ertapenem against selected respiratory pathogens. J Antimicrob Chemother 2004; 54(5): 944-951.